Ellery Paul E R, Maroney Susan A, Cooley Brian C, Luyendyk James P, Zogg Mark, Weiler Hartmut, Mast Alan E
Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI;
Department of Orthopedic Surgery, Medical College of Wisconsin, Milwaukee, WI;
Blood. 2015 Jun 25;125(26):4078-84. doi: 10.1182/blood-2015-03-633958. Epub 2015 May 7.
Tissue factor pathway inhibitor (TFPI) is a critical anticoagulant protein present in endothelium and platelets. Mice lacking TFPI (Tfpi(-/-)) die in utero from disseminated intravascular coagulation. They are rescued by concomitant tissue factor (TF) deficiency, demonstrating that TFPI modulates TF function in vivo. Recent studies have found TFPI inhibits prothrombinase activity during the initiation of coagulation and limits platelet accumulation during thrombus formation, implicating TFPI in modulating platelet procoagulant activity. To examine whether altered platelet function would compensate for the lack of TFPI and rescue TFPI-null embryonic lethality, Tfpi(+/-) mice lacking the platelet thrombin receptor, protease activated receptor 4 (PAR4; Par4(-/-)), or its coreceptor, PAR3, were mated. PAR3 deficiency did not rescue Tfpi(-/-) embryos, but >40% of expected Tfpi(-/-):Par4(-/-) offspring survived to adulthood. Adult Tfpi(-/-):Par4(-/-) mice did not exhibit overt thrombosis. However, they had focal sterile inflammation with fibrin(ogen) deposition in the liver and elevated plasma thrombin-antithrombin complexes, indicating activation of coagulation at baseline. Tfpi(-/-):Par4(-/-) mice have platelet and fibrin accumulation similar to Par4(-/-) mice following venous electrolytic injury but were more susceptible than Par4(-/-) mice to TF-induced pulmonary embolism. In addition, ∼30% of the Tfpi(-/-):Par4(-/-) mice were born with short tails. Tfpi(-/-):Par4(-/-) mice are the first adult mice described that lack TFPI with unaltered TF. They demonstrate that TFPI physiologically modulates thrombin-dependent platelet activation in a manner that is required for successful embryonic development and identify a role for TFPI in dampening intravascular procoagulant stimuli that lead to thrombin generation, even in the absence of thrombin-mediated platelet activation.
组织因子途径抑制剂(TFPI)是一种存在于内皮细胞和血小板中的关键抗凝蛋白。缺乏TFPI(Tfpi(-/-))的小鼠会因弥散性血管内凝血在子宫内死亡。同时缺乏组织因子(TF)可挽救它们的生命,这表明TFPI在体内调节TF的功能。最近的研究发现,TFPI在凝血起始阶段抑制凝血酶原酶活性,并在血栓形成过程中限制血小板聚集,提示TFPI参与调节血小板促凝活性。为了研究血小板功能改变是否能弥补TFPI的缺失并挽救TFPI基因敲除小鼠的胚胎致死性,将缺乏血小板凝血酶受体、蛋白酶激活受体4(PAR4;Par4(-/-))或其共受体PAR3的Tfpi(+/-)小鼠进行交配。PAR3缺乏并不能挽救Tfpi(-/-)胚胎,但超过40%预期的Tfpi(-/-):Par4(-/-)后代存活至成年。成年Tfpi(-/-):Par4(-/-)小鼠未表现出明显的血栓形成。然而,它们出现了局灶性无菌性炎症,肝脏中有纤维蛋白(原)沉积,血浆凝血酶 - 抗凝血酶复合物升高,表明基线时凝血被激活。Tfpi(-/-):Par4(-/-)小鼠在静脉电解损伤后,血小板和纤维蛋白的积累与Par4(-/-)小鼠相似,但比Par4(-/-)小鼠更易发生TF诱导的肺栓塞。此外,约30%的Tfpi(-/-):Par4(-/-)小鼠出生时尾巴短小。Tfpi(-/-):Par4(-/-)小鼠是首个被描述的缺乏TFPI且TF未改变的成年小鼠。它们表明TFPI以一种成功胚胎发育所需的方式生理调节凝血酶依赖性血小板激活,并确定了TFPI在抑制导致凝血酶生成的血管内促凝刺激中的作用,即使在没有凝血酶介导的血小板激活的情况下也是如此。